EdenTree Asset Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.52M Hold
25,000
0.46% 45
2025
Q4
$1.35M Hold
25,000
0.41% 45
2025
Q3
$1.13M Hold
25,000
0.27% 50
2025
Q2
$1.16M Hold
25,000
0.32% 49
2025
Q1
$1.53M Hold
25,000
0.51% 42
2024
Q4
$1.41M Hold
25,000
0.41% 51
2024
Q3
$1.29M Hold
25,000
0.37% 51
2024
Q2
$1.04M Hold
25,000
0.33% 55
2024
Q1
$1.36M Sell
25,000
-67,450
-73% -$3.44M 0.43% 42
2023
Q4
$4.74M Buy
92,450
+3,000
+3% +$157K 1.47% 23
2023
Q3
$5.19M Buy
89,450
+12,000
+15% +$735K 2.04% 20
2023
Q2
$4.95M Buy
+77,450
New +$5.19M 1.7% 22

Other funds holding BMY

EdenTree Asset Management's BMY Position: Q1 2026 in Review

EdenTree Asset Management held its Bristol-Myers Squibb (BMY) position steady in Q1 2026 at 25,000 shares worth $1.52M. The position accounts for 0.46% of the portfolio, ranked #45.

EdenTree Asset Management first reported a position in BMY in Q2 2023 and has held it in 12 quarters since. The position peaked at $5.19M in Q3 2023. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • EdenTree Asset Management held 25,000 shares of Bristol-Myers Squibb worth $1.52M as of Q1 2026.
  • EdenTree Asset Management left its Bristol-Myers Squibb share count unchanged in Q1 2026.
  • Bristol-Myers Squibb made up 0.46% of EdenTree Asset Management's portfolio in Q1 2026, its #45 holding.
  • EdenTree Asset Management first reported a position in Bristol-Myers Squibb in Q2 2023 and has held it in 12 quarters since.
  • EdenTree Asset Management's Bristol-Myers Squibb position peaked at $5.19M in Q3 2023.
  • 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on EdenTree Asset Management's 13F filing for Q1 2026, filed 14 May 2026.